Systematic Review with Meta-analysis of ''Role of Rituximab in Treatment of Bullous Auto-immune Diseases''

Sayed, Amany Mokhtar Abdallah; Gohary, Yasser Mostafa; Ahmed, Mona Elsayed

doi:10.21608/ejmr.2022.151802.1252

Systematic Review with Meta-analysis of ''Role of Rituximab in Treatment of Bullous Auto-immune Diseases''

Document Type : Original Article

Authors

Dermatology Department, Faculty of Medicine, Beni-Suef University

10.21608/ejmr.2022.151802.1252

Abstract

Background: Autoimmune bullous disorders (AIBDs) are a diverse collection of uncommon illnesses, clinically defined by the presence of erosions and/or blisters. Bullous skin illnesses are classified into two types depending on whether the skin is afflicted inside the epidermis or at the epidermal-dermal junction. Rituximab (RTX) is a chimeric, humanized anti-CD20 monoclonal antibody thought to achieve its therapeutic effects in AIBD by depleting Dsg-specific IgG-positive B cells. RTX with short-term corticosteroids are safe and much more efficacious than corticosteroids alone Objective: To assess the safety and effectiveness of RTX in the treatment of AIBDs in comparison to placebo, conventional therapies, or other biologics. Methods: The PRISMA checklist directed the data reporting. We conducted a search in PubMed, Web of Science, Embase, ScienceDirect, and Scopus. Results: The literature review found 2310 publications. Following the evaluation of titles and abstracts according to the inclusion and exclusion criteria, and the assessment of full texts, 12 publications were ultimately included into the meta-analysis. Conclusions: RTX is both safe and efficacious for the managing AIBDs.

Keywords

Main Subjects

Internal medicine ·

References

1. Schmidt, E., & Zillikens, D. (2010). Modern diagnosis of autoimmune blistering skin diseases. Autoimmunity reviews, 10(2), 84-89.
2. Sagi, L., Baum, S., Agmon-Levin, N., Sherer, Y., Katz, B. S. P., Barzilai, O., & Shoenfeld, Y. (2011). Autoimmune bullous diseases: the spectrum of infectious agent antibodies and review of the literature. Autoimmunity reviews, 10(9), 527-535.
3. Sticherling, M., & Erfurt-Berge, C. (2012). Autoimmune blistering diseases of the skin. Autoimmunity reviews, 11(3), 226-230.
4. Colliou, N., Picard, D., Caillot, F., Calbo, S., Le Corre, S., Lim, A., & Musette, P. (2013). Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Science translational medicine, 5(175), 175ra30.
5. Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., & Musette, P. (2017). First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. The Lancet, 389(10083), 2031-2040.
6. Johnston, S., & Kennedy, C. (2005). Pemphigus foliaceus. New England Journal of Medicine, 353(24), 2589-2589.
7. Johnson, P. W., & Glennie, M. J. (2001). Rituximab: Mechanisms and applications. Br J Cancer. 2001; 85: 1619–23.
8. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., Altman, D., Antes, G., Atkins, D., Barbour, V., Barrowman, N., Berlin, J. A., Clark, J., Clarke, M., Cook, D., D’Amico, R., Deeks, J. J., Devereaux, P. J., Dickersin, K., Egger, M., Ernst, E., & Tugwell, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097.
9. Higgins, J. P., & Green, S. (2008). Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. In Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series.
10. Green, S., Higgins P., T., J., Alderson, P., Clarke, M., Mulrow D, C., & Oxman D, A. (2011). Cochrane Handbook: Cochrane Reviews: Ch 8: Assessing risk of bias in included studies. In Cochrane Handbook for: Systematic Reviews of Interventions, 6: 3–10.
11. Kim, J. H., Kim, Y. H., Kim, M. R., & Kim, S. C. (2014). Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. British Journal of Dermatology, 165(3), 646-651.
12. Kurihara, Y., Yamagami, J., Funakoshi, T., Ishii, M., Miyamoto, J., Fujio, Y., & Amagai, M. (2019). Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open label, single arm, phase 1/2 study on 10 Japanese patients. The Journal of dermatology, 46(2), 124-130.
13. Horvath, B., Huizinga, J., Pas, H. H., Mulder, A. B., & Jonkman, M. F. (2012). Low dose rituximab is effective in pemphigus. British Journal of Dermatology, 166(2), 405–412.
14. Werth, V. P., Joly, P., Mimouni, D., Maverakis, E., Caux, F., Lehane, P., & Chen, D. M. (2021). Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. New England Journal of Medicine, 384(24), 2295-2305.
15. Chen, D. M., Odueyungbo, A., Csinady, E., Gearhart, L., Lehane, P., Cheu, M., Maho Vaillant, M., Prost Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M. L., Labeille, B., Picard Dahan, C., Paul, C., Richard, M. A., Bouaziz, J. D., Duvert Lehembre, S., & Joly, P. (2020). Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect. British Journal of Dermatology, 182(5), 1111–1119.
16. Cho, Y. T., Lee, F. Y., Chu, C. Y., & Wang, L. F. (2012). First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Dermato-Venereologica, 94(4), 472–473.
17. Kanwar, A. J., Vinay, K., Sawatkar, G. U., Dogra, S., Minz, R. W., Shear, N. H., & Hashimoto, T. (2014). Clinical and immunological outcomes of high‐and low dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer blinded study. British Journal of Dermatology, 170(6), 1341-1349.
18. Wollina, U., Koch, A., & Hansel, G. (2008). Rituximab therapy of recalcitrant bullous dermatoses. Journal of dermatological case reports, 2(1), 4.
19. Arin, M. J., Engert, A., Krieg, T., & Hunzelmann, N. (2005). Anti‐CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. British Journal of Dermatology, 153(3), 620-625.
20. Kamran, B., Maryam, D., Somayeh, K., Mostafa, M. N., Mahsa, H. J., & Cheyda, C. D. (2013). Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. International journal of dermatology, 52(7), 862-867.
21. Aryanian, W. & Posner, M. R. (2021). Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. New England Journal of Medicine, 355(17), 1772-1779.
22. Wang, K., Goodman, K.N., Li, D.Y., Raffeld, M., Chavez, M. and Cohen, J.I. (2015). A herpes simplex virus 2 (HSV-2) gD mutant impaired for neural tropism is superior to an HSV-2 gD subunit vaccine to protect animals from challenge with HSV-2. Journal of virology, 90(1), pp.562-574.
23. Feliciani, C., Joly, P., Jonkman, M.F., Zambruno, G., Zillikens, D., Ioannides, D., Kowalewski, C., Jedlickova, H., Kárpáti, S., Marinovic, B. and Mimouni, D. (2015). Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. British journal of dermatology, 172(4), pp.867-877.
24. Venning, V.A., Taghipour, K., Mohd Mustapa, M.F., Highet, A.S., Kirtschig, G., Hughes, J.R., McLelland, J., McDonagh, A.J., Punjabi, S., Buckley, D.A. and Nasr, I. (2012). British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. British Journal of Dermatology, 167(6), pp.1200-1214.
25. Zambruno, G., & Borradori, L. (2008). Rituximab Immunotherapy in Pemphigus: Therapeutic Effects Beyond B-Cell Depletion. Journal of Investigative Dermatology, 128(12), 2745–2747.
26. Meyer, V., & Beissert, S. (2011). Azathioprine in the treatment of autoimmune blistering diseases. Dermatologic clinics, 29(4), 545-554.
27. Craythorne, E. E., & Mufti, G. (2011). Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. Journal of the American Academy of Dermatology, 65(5), 1064–1065.
28. Kanwar, A. J., Tsuruta, D., Vinay, K., Koga, H., Ishii, N., Dainichi, T., & Hashimoto, T. (2013). Efficacy and safety of rituximab treatment in Indian pemphigus patients. Journal of the European Academy of Dermatology and Venereology, 27(1), e17–e23.
29. Lunardon, L., Tsai, K. J., Propert, K. J., Fett, N., Stanley, J. R., Werth, V. P., Tsai, D. E., & Payne, A. S. (2012). Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Archives of Dermatology, 148(9), 1031–1036.
30. Lunardon, L., & Payne, A. S. (2012). Inhibitory human anti-chimeric antibodies to rituximab in a pemphigus patient. The Journal of allergy and clinical immunology, 130(3), 800.
31. Matsukura, S., Knowles, S. R., Walsh, S., & Shear, N. H. (2012). Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus. Archives of Dermatology, 148(6).
32. Anandan, V., Jameela, W. A., Sowmiya, R., Kumar, M. M. S., & Lavanya, P. (2017). Rituximab: a magic bullet for pemphigus. Journal of clinical and diagnostic research: JCDR, 11(4), WC01.